RAS Signal Strength Shapes Cellular Senescence and Cancer Risk
New research shows that the level of RAS oncogene activity determines whether cells become senescent or tumorigenic β a key cancer-prevention insight.
516 articles in this topic
New research shows that the level of RAS oncogene activity determines whether cells become senescent or tumorigenic β a key cancer-prevention insight.
Dive deep into the molecular machinery of genomic instability β from telomere-driven crisis states and epigenetic remodeling at break sites to cutting-edge therapeutic strategies targeting DNA repair fidelity in aging and cancer.
Discover what DNA actually is, how everyday threats like sunlight and stress can damage it, and why protecting your genetic code is the secret to a longer, healthier life.
Zongertinib (Hernexeos) wins FDA approval for unresectable or metastatic HER2-mutant non-squamous NSCLC, expanding targeted therapy options.
A Danish cohort of 49,894 adults shows first-time seizures carry a 76-fold elevated risk of neurological cancer and double the risk of non-neurological cancers within one year.
Scientists discover that maintaining proteostasis in tumor-infiltrating lymphocytes prevents exhaustion and boosts immunotherapy outcomes.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
A new agentic AI framework autonomously generates biological concepts from pathology images, identifying prognostic and predictive cancer biomarkers without manual feature engineering.
A novel cell-labeling tool reveals how ERΞ±+ macrophages create immune-excluded niches in bone, blocking T cells from destroying cancer.
Specific mutational signatures accumulate linearly with age in normal tissues, offering a new window into why cancer risk rises exponentially as we get older.
A clinical trial in Nature Cancer shows an AI model meaningfully boosts diagnostic accuracy for lung nodules, a critical step in early cancer detection.
A 156-patient multimodal study reveals two distinct immune microenvironments in breast cancer brain metastases that predict survival and immunotherapy response.